Market Currents
Neoprobe (NEOP) jumps 4.5% AH after announcing it has licensed worldwide exclusive rights to...
-
Monday, December 12, 2011, 4:53 PM ETNeoprobe (NEOP) jumps 4.5% AH after announcing it has licensed worldwide exclusive rights to AstraZenaca's (AZN) AZD4694 patient imaging solution, and plans to initiate Phase III trials in early 2013. Neoprobe will pay AstraZanaca a $5M up-front licensing fee, as well as future milestone payments and royalties.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
